The neuroendocrinology of chronic fatigue syndrome and fibromyalgia

Psychological Medicine

Volumn 31, Issue 8, 2001, Pages 1331-1345

  Parker, A J R ^a   Wessely, S ^a   Cleare, A J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; BUSPIRONE; CORTICOTROPIN; DEXFENFLURAMINE; FLUDROCORTISONE; GLUCOCORTICOID; GROWTH HORMONE; HYDROCORTISONE; IPSAPIRONE; NALOXONE; NEUROTRANSMITTER; OPIATE; PROLACTIN; SEROTONIN;

BEHAVIOR; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; DATA BASE; EXERCISE; FIBROMYALGIA; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LONGITUDINAL STUDY; METHODOLOGY; NEUROENDOCRINOLOGY; PATHOPHYSIOLOGY; POPULATION RISK; REVIEW; SLEEP; SYMPTOMATOLOGY;

EID: 0034755665     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0033291701004664     Document Type: Review

References (98)

1. Changes in growth hormone, insulin, insulin-like growth factors (IGFS), and IGF-binding protein-1 in chronic fatigue syndrome
2. Vasopressinergic control of pituitary adenocorticotrophin secretion comes of age
3. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome
4. Abnormal arginine-vasopressin secretion and water metabolism in patients with postviral fatigue syndrome
5. The adrenal cortex
6. Neuroendocrine response to D-fenfluramine and insulin-induced hypoglycaemia in chronic fatigue syndrome
7. Somatomedin C (insulin-like growth factor I) levels in patients with chronic fatigue syndrome
8. Low levels of somatomedin C in patients with fibromyalgia
9. A randomized double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia
10. Secretion of growth hormone in patients with chronic fatigue syndrome
11. The relationship between neurally mediated hypotension and the chronic fatigue syndrome
12. Intraventricular corticotrophin-releasing factor enhances behavioural effects of novelty
13. Frequency of 'chronic active Epstein-Barr virus infection' in a general medical practice
14. Neuroendocrine regulation in depression. I: Limbc system-adrenocortical dysfunction
15. Physiopharmacological interactions between stress hormones and central serotonergic systems
16. Neuroendocrine tests of monoamine function in man: A review of basic theory and its application to the study of depressive illness
17. The neuroendocrinology of depression and of chronic stress
18. Contrasting neuroendocrine response in depression and chronic fatigue syndrome
19. Reduced prolactin and cortisol responses to D-fenfluramine in depressed compared to healthy matched control subjects
20. Low-dose hydrocortisone in chronic fatigue syndrome: A randomised crossover trial
21. Integrity of the GH/IGF system is maintained in patients with chronic fatigue syndrome
22. Urinary free cortisol in chronic fatigue syndrome
23. Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy
24. Decreased immunoreactive beta-endorphin in mononuclear leucocytes from patients with chronic fatigue syndrome
25. Serotonin receptor subtypes in depression: Evidence from studies in neuroendocrine regulation
26. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia
27. Postviral fatigue syndrome and psychiatry
28. Selective control by corticosterone of serotonin-1 receptors capacity in raphe-hippocampal system
29. Glucocorticoids, transmitters and stress
30. Neuroendocrine correlates of chronic fatigue syndrome: A brief review
31. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome
32. The combined dexamethasone/cortocotrophin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamic-pituitary-adrenocortical system than the dexamethasone test
33. Glucocorticoids and the genesis of depressive illness. A psychobiological model
34. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function
35. Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome
36. A long term increase in basal levels of corticosterone and a decrease in corticosteroid-binding globulin after acute stressor exposure
37. The chronic fatigue syndrome: A comprehensive approach to its definition and study
38. Further studies of the corticosteroid-binding globulin in the rat: Proposed endocrine control
39. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome
40. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain
41. The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders
42. A randomized, double-blind, placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome
43. A cluster of patients with a chronic mononeucleosis-like syndrome: Is Epstein-Barr virus the cause?
44. Long-term serological follow-up of patients with Epstein-Barr virus after recovery from infectious mononucleosis
45. The 1 mg short synacthen test in chronic fatigue syndrome
46. A comparison of the naloxone test with ovine CRH and insulin hypoglycaemia in the evaluation of the hypothalamic-pituitary-adrenal axis: Interaction with endogenous opioid peptides
47. Immunoradiometric assay of succinylated corticotrophin: An improved method for quantification of ACTH
48. Salivary cortisol in psychoneuroendocrine research: Recent developments and applications
49. Corticotrophin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotrophin release in man
50. Plasma cortisol in psychiatric and neurological patients with pain
51. Short-term night-shift working mimics the pituitary-adrenocortical dysfunction of chronic fatigue syndrome
52. 1A) receptor mediated hypothermic response to ipsapirone in unipolar depression
53. The pathophysiology of depression: A synthesis of the role of serotonin and cortocosteroids
54. Mood and neuropsychological function in depression: The role of corticosteroids and serotonin
55. Diurnal hormone variation in fibromyalgia: A comparison with rheumatoid arthritis
56. Diurnal variation of adrenocortical activity in chronic fatigue syndrome
57. Low-dose hydrocortisone for treatment of chronic fatigue syndrome: A randomized controlled trial
58. Prolactin response to buspirone challenge in the presence of dopaminergic blockade
59. Neuroendocrine effects of buspirone: Mediation by dopaminergic and serotonergic mechanisms
60. Musculoskeletal symptoms and non-REM sleep disturbance in patients with 'fibrositis syndrome' and healthy subjects
61. Effect of growth hormone treatment in patients with chronic fatigue syndrome
62. Clinical evaluations of urinary cortisol determination by competitive protein-binding radioassay
63. Randomized, double-blind, placebo-phase in trial of low-dose phenelzine in the chronic fatigue syndrome
64. Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome
65. Impaired HPA axis activity in chronic fatigue syndrome and fibromyalgia
66. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome
67. Hormone pulsatility discrimination via coarse and short time sampling
68. Adrenocortical activity and some clinical findings in chronic fatigue
69. Neuroendocrine aspects of chronic fatigue syndrome
70. Sex differences in the human metabolism of cortisol
71. Long term outcome of bilateral adrenalectomy in patients with Cushing's syndrome
72. The effect of glucocorticoids on corticosteroid binding globulin
73. Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers
74. Blunted adrenocorticotrophin and cortisol responses to corticotrophin-releasing hormone stimulation in chronic fatigue syndrome
75. The low dose adrenocorticotrophin test in chronic fatigue syndrome and in health
76. Naloxone-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome
77. Small adrenal glands in chronic fatigue syndrome: A preliminary computer tomography study
78. Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers
79. Chronic fatigue syndrome: Guidelines for research
80. Increased prolactin response to buspirone in chronic fatigue syndrome
81. Increased brain serotonin function in men with chronic fatigue syndrome
82. Chronic social stress produces reductions in available splenic type II corticosteroid receptor binding and plasma corticosteroid binding globulin levels
83. Pre-treatment DST and hypothalamic-pituitary-adrenocortical function in depressed patients and comparison groups. A multicenter study
84. A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls
85. Corticotrophin-releasing factor produces behavioural activation in rats
86. Corticotrophin-releasing factor potentiates acoustic startle in rats: Blockade by chlordiazepoxide
87. Hypoadrenia, or 'a bit of Addison's disease'
88. Beta-endorphin suppresses adrenocorticotrophin and cortisol levels in normal human subjects
89. Physiological and clinical relevance or endorphins
90. Neuroendocrine aspects of primary endogenous depression. 12. Receiver operating characteristics and kappa analyses of serum and urine cortisol measure in patients and matched controls
91. Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): Is PFS a disorder of neuroendocrine reactivity?
92. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome
93. Functional somatic syndromes: One or many?
94. Incidence, risk and prognosis of acute and chronic fatigue syndromes and psychiatric disorders after glandular fever
95. Salivary cortisol profiles in chronic fatigue syndrome
96. Neuroendocrine assessment of serotonin (5-HT) function in chronic fatigue syndrome
97. Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia)